SCHEMBL5566656

SCHEMBL5566656

COCCOCCOc1cc2ncnc(Oc3cc(-c4ccccc4)[nH]n3)c2cc1OC

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ KDM1A O60341 3/20 0.53
▸ RAF1 P04049 5/20 0.44
▸ BRAF P15056 5/20 0.44
▸ IRAK1 P51617 1/20 0.44
▸ IRAK4 Q9NWZ3 1/20 0.44
▸ KDR P35968 5/20 0.43
▸ CSF1R P07333 2/20 0.43
▸ PDGFRB P09619 2/20 0.43
▸ FLT3 P36888 2/20 0.43
▸ FLT4 P35916 1/20 0.43
▸ FGFR1 P11362 1/20 0.42
▸ FLT1 P17948 1/20 0.42
▸ FBP1 P09467 1/20 0.42
▸ EGFR P00533 2/20 0.41
▸ RET P07949 1/20 0.41
▸ KIF5B P33176 1/20 0.41
▸ LCK P06239 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL5566338 0.99 KDM1A (0.52) KDM1ARAF1BRAFIRAK1IRAK4
SCHEMBL5565868 0.97 KDM1A (0.56) KDM1ARAF1BRAFIRAK1IRAK4
Hydrochloric Acid SCHEMBL5566986 0.96 KDM1A (0.55) KDM1ARAF1BRAFIRAK1IRAK4
SCHEMBL7888723 0.94 KDM1A (0.52) KDM1ARAF1BRAFIRAK1IRAK4
SCHEMBL5566781 0.89 EGFR (0.50) BRAFIRAK1IRAK4KDRCSF1R
SCHEMBL5565927 0.89 KDM1A (0.54) KDM1ARAF1BRAFKDRCSF1R
SCHEMBL5565932 0.83 KDR (0.60) RAF1BRAFKDRCSF1RPDGFRB
SCHEMBL7884841 0.83 KDM1A (0.41) KDM1ABRAFIRAK1IRAK4KDR
SCHEMBL7885709 0.83 KDR (0.53) KDRCSF1RPDGFRBFLT3FLT4
SCHEMBL5566917 0.82 EGFR (0.49) KDM1AIRAK1IRAK4KDRCSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7262201-B1 For the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals ASTRAZENECA AB (SE) 2007-08-28 — — US claimed
EP-1119567-B1 QUINAZOLINE DERIVATIVES ASTRAZENECA AB (SE) 2005-05-04 — — EP claimed
US-7262201-B1 For the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals ASTRAZENECA AB (SE) 2007-08-28 — — US disclosed
EP-1119567-B1 QUINAZOLINE DERIVATIVES ASTRAZENECA AB (SE) 2005-05-04 — — EP disclosed
EP-1119567-A1 QUINAZOLINE DERIVATIVES AstraZeneca AB (SE) 2001-08-01 — — EP disclosed
WO-2000021955-A1 QUINAZOLINE DERIVATIVES ASTRAZENECA AB (SE) 2000-04-20 — — WO disclosed
Send feedback